BioSpace News Archive

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, reported financial results and business highlights for the third quarter ended September 30, 2019.

Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will effect a one-for-15 reverse stock split of its common stock that will become effective on November 14, 2019 after the close of trading on The Nasdaq Global Market.

MYOS RENS Technology Inc., an advanced nutrition company and the owner of Fortetropin®, an innovative proprietary bioactive composition made from fertilized egg yolks that helps build lean muscle, announced its financial results for the three and nine months ended September 30, 2019.

Life Spine, Inc. is pleased to announce that it has entered into a settlement agreement with the U.S. government that successfully resolves all of the government’s claims.

AbbVie Inc. announced today that the requisite number of consents have been received to adopt certain proposed amendments with respect to all outstanding notes of certain series issued by Allergan Finance, LLC (“Allergan Finance”), Allergan, Inc. (“Allergan Inc”), Allergan Sales, LLC (“Allergan Sales”) and Allergan Funding SCS

Cidara Therapeutics, Inc. reported financial results for the three months ended September 30, 2019 and provided an update on its corporate activities and product pipeline.

Agios Pharmaceuticals, Inc. announced that it has priced an underwritten public offering of 8,250,000 shares of common stock at a price to the public of $31.00 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $256 million.

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced its financial results for the third quarter ended September 30, 2019.

Trovagene, Inc., a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division for the treatment of various cancers including prostate, colorectal and leukemia, announced company highlights and financial results for the third quarter ended September 30, 2019.

Entera Bio Ltd., announced that it will report financial results for the third quarter and nine months ended September 30, 2019 before the U.S. financial markets open on Thursday, November 21, 2019..